Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer

Sponsor
Fujian Medical University
Study ID
NCT05643677
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fruquintinib — DRUG
    4 mg PO, QD (3 weeks on, 1 week off)
  • Irinotecan — DRUG
    participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks

Study Details

This study explores the efficacy and safety of fruquintinib combined with irinotecan in the second-line treatment of patients with advanced gastric cancer, aiming to bring more second-line treatment options for patients with advanced gastric cancer.

Key Dates

Start date
Dec 31, 2022
Status verified
Dec 2022
Primary completion
Nov 30, 2024
Completion
Nov 30, 2025

Study Design

Enrollment
47 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Fruquintinib combined with irinotecan
    Fruquintinib combined with irinotecan as a second-line treatment for advanced gastric cancer

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]

Central Contacts

Related Studies